Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer Strikes Supply Agreement With Imugene, Merck KGaA for Clinical Trial of Gastric Cancer Treatment

11/17/2021 | 08:48am EST


ę MT Newswires 2021
All news about PFIZER, INC.
05:35aCanadian Regulator Approves Pfizer's COVID-19 Treatment Paxlovid
MT
04:40aExperts stress Pfizer's antiviral COVID-19 treatment not a replacement for vaccines
AQ
04:37aPfizer Adds Novasep to Global Supply Chain for Paxlovid Pill
MT
01:21aPfizer boss says 'normal life' to return in spring
AQ
01/17Canada approves Pfizer's antiviral COVID-19 treatment for use
AQ
01/17Health Canada approves Pfizer antiviral but supply issues expected
AQ
01/17A look at the latest COVID-19 developments in Canada
AQ
01/17Canada approves Pfizer COVID drug as hospitalizations rise and kids return to school
AQ
01/17Canada study of Merck's COVID-19 oral treatment is moving more slowly - health minister
RE
01/17Canada approves Pfizer COVID drug
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 916 M - -
Net income 2021 22 210 M - -
Net Debt 2021 27 661 M - -
P/E ratio 2021 14,4x
Yield 2021 2,88%
Capitalization 308 B 308 B -
EV / Sales 2021 4,10x
EV / Sales 2022 3,31x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 54,95 $
Average target price 57,10 $
Spread / Average Target 3,90%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-6.94%308 427
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.10%325 363
ABBVIE INC.0.35%240 202
NOVO NORDISK A/S-15.01%223 075
ELI LILLY AND COMPANY-11.62%221 317